Table 1. Clinicopathological characteristics of patients with HR+/HER2− breast cancer included in our study.
| Variables | HR+/HER2− breast cancer cohort (N=421) |
|---|---|
| Age, years | |
| ≤50 | 173 (41.1) |
| >50 | 248 (58.9) |
| T category | |
| T1 | 199 (47.3) |
| T2 | 218 (51.8) |
| T3 | 3 (0.7) |
| NA | 1 (0.2) |
| N category | |
| N0 | 190 (45.1) |
| N1 | 134 (31.9) |
| N2 | 59 (14.0) |
| N3 | 38 (9.0) |
| Tumor grade | |
| I–II | 284 (67.5) |
| III | 117 (27.8) |
| Unknown | 20 (4.8) |
| Surgery type | |
| Non-BCS | 417 (99.0) |
| BCS | 4 (1.0) |
| Radiotherapy | |
| No | 253 (60.1) |
| Yes | 128 (30.4) |
| Unknown | 40 (9.5) |
| Chemotherapy | |
| No | 86 (20.4) |
| Yes | 312 (74.1) |
| Unknown | 23 (5.5) |
| Endocrine therapy | |
| No | 11 (2.61) |
| Yes | 359 (85.27) |
| Unknown | 51 (12.12) |
Data are presented as number (percentage) of patients. BCS, breast conserving surgery.